DR REDDYS LABS PPT

WELCOME
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

Dr Reddy’s Laboratories
The Home-grown Pharmaceutical Giant
Company Based Research
Presentation
MANASH PRATIM KALITA
ROLL NO-198
SECTION-M4

Introduction
 Dr.Reddy’s laboratories is a premier and major Indian pharmaceutical
company headquartered in hyderabad
 Founded by Kallam Anji Reddy in 1984
 Over 190 medications, 60 active pharmaceutical ingredients(api) for drug
manufacture, diagnostic kits and critical care units
 To bring new molecules into the country at a price the common man can afford
 Global workforce-20000+
 Commercial presence-26 countries

Group Companies
 Dr. Reddy's laboratories Australia pvt ltd, a wholly owned subsidiary of dr.
Reddy's laboratories ltd
 In china joint venture with Rotam group
 Dr. Reddy's operates in Germany through its subsidiary Betapharm
 Dr. Reddy’s laboratories ltd. decided to enter the market directly through a
joint venture with Venturepharm
 Dr. Reddy’s laboratories UK ltd was created with the acquisition of BMS
laboratories and its subsidiary meridian healthcare

 Goal
 Good health
 Commitment
 That’s why the company believes in “Good health cant wait”
 Principles
 Empathy and Dynamism
 Purpose
 We accelerate access to affordable and innovative medicines because good
health cant wait

Hierarchy and Organizational
Structure
CHAIRMAN
COO
GLOBAL HR
HEAD
EVP CFO
CO-CHAIRMAN
CUM CEO
Whole time directors
 Satish Reddy
 G V Prasad
Independent and non-whole time directors
 Dr.Omkar Goswami
 Anupam Puri
 Kalpana Morparia
 Dr. Bruce LA Carter

Products and Services
 GENERICS- Omez (Omeprazole), Nise (Nimesulide),Ketorol
(Ketorolac Thromethamine), Stamlo (Amlodipine Besylate), Razo
(Rabeprazole)
 OVER THE COUNTER- Cetrine, Nise gel, Ibuclin and Novigan.US nicotine
replacement therapy transdermal patch named Habitrol.
 API(ACTIVE PHARMACEUTICAL INGREDIENTS)- caters to leading
innovator and generic companies across the US, Europe, Latin America, Japan,
Korea and other emerging markets such as steroids, peptides, complex long
chain synthesis and oncology
 BIOLOGICS- Biologics – large molecule protein therapies – for an effective
treatment that may have fewer side effects.
 DIFFERENTIATED FORMULATIONS- Custom Pharma Services (CPS)

Major Competitors of the Company
 Sun Pharma
 Lupin
 Aurobindo Pharma
 Cipla
 Cadila
 Ranbaxy Labs
 Divis labs
International Competitors
 Abbot Laboratories
 Abeona Therapeutics

NAME
SALES
TURNOVER
MARKET SHARE IN
%
Sun Pharma 7,614.46 8.137796832
Lupin 11,239.80 12.01230407
Dr Reddys Labs 10,207.70 10.90926851
Aurobindo Pharm 9,166.18 9.796165527
Cipla 12,034.06 12.86115303
Cadila Health 7,035.30 7.518831545
Ranbaxy Labs 6,864.94 7.336762815
Divis Labs 3,721.33 3.977094565
Piramal Enter 3,516.53 3.758218796
GlaxoSmithKline 2,826.21 3.020453556
Torrent Pharma 5,429.00 5.802131602
Glenmark 6,113.50 6.533676837
Alkem Lab 3,924.69 4.194431364
Biocon 2,323.60 2.483299501
Ajanta Pharma 1,551.76 1.658411445
TOTAL 93,569.06 100
8.137796832
12.01230407
10.90926851
9.796165527
12.86115303
7.518831545
7.336762815
3.977094565
3.758218796
3.020453556
5.802131602
6.533676837
4.194431364 2.483299501
1.658411445
MARKET SHARE IN %
Sun Pharma Lupin Dr Reddys Labs Aurobindo Pharm
Cipla Cadila Health Ranbaxy Labs Divis Labs
Piramal Enter GlaxoSmithKline Torrent Pharma Glenmark
Alkem Lab Biocon Ajanta Pharma
Market Share

Ownership
PARTICULARS % OF SHARES
Promoter(individual and companies) 26.37
Indian financial institutions 2.83
Banks 0.15
Mutual funds 2.76
FIIs 35.41
NRIs 1.25
Foreign Companies 2.98
Indian Public 11.40

Strength
1.Low cost chemotherapy medicine
2.Proprietary chiral and
biocatalysis know-how
3.Betapharma acquisition gives
access to European markets
Weakness
1.Government regulations and
national drug policy
2.Huge investment
3.Highly unpredictable sector
Opportunities
1.Oncology market entry
2.Partnership in bio-similar markets
3.Cost effective methodologies in
emerging markets
Threats
1.Preliminary investment very high
2.Patents
3.Foreign giant entry

Financial Analysis
1.7101590481.8875074852.0380409912.1175990332.269833634
0
1
2
3
2011 2012 2013 2014 2015 2016 2017
DEBT
EQUITY
RATIO

CSR Activities
 School-Community Partnership in Education
 Chindu
 Pudami Neighborhood Schools
 KARV – Kallam Anji Reddy Vidyalaya
 KARV-JC – Kallam Anji Reddy Vocational Junior College
 Youth
 Women
 Household

CSR Expenditure
 2016---3.04%
 2014-15---1.74%
 2013-14---1.03%
 2012-13---1.33%
 CSR provisions in Companies Act,2013
 every company, private limited or public limited, which either has a net worth of Rs 500 crore or a
turnover of Rs 1,000 crore or net profit of Rs 5 crore, needs to spend at least 2% of its average net
profit for the immediately preceding three financial years on corporate social responsibility
activities

Employee Benefits

Economic Analysis
 High economies of scale
 Low cost products so tough entry for players
 Extensive R&D hence no threats from patent expiration
 Alliances, joint ventures or acquisition
 Easing of norms under “Make in India” programme

Conclusion
 Made healthcare more affordable
 Giant Indian player in US, Russia and CIS countries
 FDA regulations getting tougher
 Currently focus is not only on foreign countries but also in India
 NYSE listed company

THANK YOU

DR REDDYS LABS PPT

More Related Content

What's hot (20)

Viewers also liked (15)

Similar to DR REDDYS LABS PPT (20)

DR REDDYS LABS PPT